Hyperparathyroidism differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 34: | Line 34: | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan=" | ! colspan="9" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF||Differential diagnosis of hyperparathyroidism on the basis of hypercalcemia}} | ||
|- | |- | ||
! colspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Disorder}} | ! colspan="2" rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Disorder}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Mechanism of hypercalcemia}} | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Mechanism of hypercalcemia}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Laboratory findings}} | ! colspan="4" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Laboratory findings}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Imaging & diagnostic modalities}} | ! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Imaging & diagnostic modalities}} | ||
|- | |||
!PTH | |||
!Calcium | |||
!Phosphate | |||
!Other findings | |||
! | |||
|- | |- | ||
| rowspan="3" style="background: #F0FFFF; text-align: center;" |'''Hyperparathyroidism''' | | rowspan="3" style="background: #F0FFFF; text-align: center;" |'''Hyperparathyroidism''' | ||
Line 49: | Line 55: | ||
* Hypercalcemia detected on routine biochemical panel | * Hypercalcemia detected on routine biochemical panel | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* ↑ | * ↑ | ||
|↑ | |||
|''↓''/Normal | |||
|Normal/↑ calcitriol | |||
| rowspan="3" style="background: #DCDCDC;" |Findings of bone resorption: | | rowspan="3" style="background: #DCDCDC;" |Findings of bone resorption: | ||
* X-ray | * X-ray | ||
Line 78: | Line 84: | ||
** Vitamin D deficiency | ** Vitamin D deficiency | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* '''↑''' | * '''↑''' | ||
|'''↓/'''Normal | |||
|''↑'' | |||
| | |||
|- | |- | ||
| style="background: #F0FFFF; text-align: center;" |Tertiary hyperparathyroidism | | style="background: #F0FFFF; text-align: center;" |Tertiary hyperparathyroidism | ||
Line 89: | Line 96: | ||
* Usually hyperplasia of all four parathyroid glands | * Usually hyperplasia of all four parathyroid glands | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* '''↑''' | * '''↑''' | ||
|'''''↑''''' | |||
|''↑'' | |||
| | |||
|- | |- | ||
| colspan="2" style="background: #F0FFFF; text-align: center;" |Familial hypocalciuric hypercalcemia | | colspan="2" style="background: #F0FFFF; text-align: center;" |Familial hypocalciuric hypercalcemia | ||
Line 99: | Line 107: | ||
* This is a benign condition and does not require treatment. | * This is a benign condition and does not require treatment. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Normal'''/↑''' | * Normal'''/↑''' | ||
|Normal/'''''↑''''' | |||
| | |||
| | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Calcium/creatinine clearance ratio | * Calcium/creatinine clearance ratio | ||
Line 111: | Line 121: | ||
* Usually present in solid tumors | * Usually present in solid tumors | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* | * | ||
|'''''↑''''' | |||
|'''↓'''/Normal | |||
|'''↑''' PTHrP | |||
Normal/↑ calcitriol | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Chest X-ray | * Chest X-ray | ||
Line 125: | Line 137: | ||
* Most commonly present in multiple myeloma and breast cancer. | * Most commonly present in multiple myeloma and breast cancer. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* '''''↓''''' | * '''''↓''''' | ||
|'''↑''' | |||
| | |||
| | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* DXA | * DXA | ||
Line 140: | Line 154: | ||
* Most commonly present in lymphomas and in some ovarian germ cell tumors. | * Most commonly present in lymphomas and in some ovarian germ cell tumors. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* '''↑''' | * Calcium | ||
* | |||
|'''↑''' | |||
| | |||
|↑ Calcitriol | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* CT scan | * CT scan | ||
Line 155: | Line 172: | ||
* ''↓''/Normal phosphate | * ''↓''/Normal phosphate | ||
* N/↑ Calcitriol | * N/↑ Calcitriol | ||
| | |||
| | |||
| | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Chest X-ray | * Chest X-ray | ||
Line 168: | Line 188: | ||
* ↑ PTH | * ↑ PTH | ||
* ↑ Calcium | * ↑ Calcium | ||
| | |||
| | |||
| | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Lithium levels | * Lithium levels | ||
Line 178: | Line 201: | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* ↑ Calcium | * ↑ Calcium | ||
| | |||
| | |||
| | |||
| style="background: #DCDCDC;" | -- | | style="background: #DCDCDC;" | -- | ||
|- | |- | ||
Line 192: | Line 218: | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* ↑ Calcium | * ↑ Calcium | ||
| | |||
| | |||
| | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Renal function test | * Renal function test | ||
Line 205: | Line 234: | ||
* '''↑''' Calcium | * '''↑''' Calcium | ||
* ↑ Vitamin D (calcidiol and/or calcitriol) | * ↑ Vitamin D (calcidiol and/or calcitriol) | ||
| | |||
| | |||
| | |||
| style="background: #DCDCDC;" | -- | | style="background: #DCDCDC;" | -- | ||
|- | |- | ||
Line 222: | Line 254: | ||
* ↑ Calcitriol | * ↑ Calcitriol | ||
* ↑ ACE levels | * ↑ ACE levels | ||
| | |||
| | |||
| | |||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* Chest X-ray | * Chest X-ray |
Revision as of 16:39, 12 September 2017
Hyperparathyroidism Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hyperparathyroidism differential diagnosis On the Web |
American Roentgen Ray Society Images of Hyperparathyroidism differential diagnosis |
Risk calculators and risk factors for Hyperparathyroidism differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
There are three types of hyperparathyroidism (primary, secondary, and tertiary) and should be differentiated between each other. Hyperparathyroidism should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia other than hyperparathyroidism include familial hypocalciuric hypercalcemia, hypercalcemia related to malignancy, medication-induced hypercalcemia, hypercalcemia due to nutritional disorders, and hypercalcemia related to granulomatous diseases.
Differentiating hyperparathyroidism from other diseases
There are three types of hyperparathyroidism (primary, secondary, and tertiary) and should be differentiated between each other. Hyperparathyroidism should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia include:
- Parathyroid related
- Hyperparathyroidism
- Primary hyperparathyroidism
- Secondary hyperparathyroidism
- Tertiary hyperparathyroidism
- Familial hypocalciuric hypercalcemia
- Hyperparathyroidism
- Non-parathyroid related
- Malignancy
- Humoral hypercalcemia of malignancy
- Osteolytic tumors
- Production of calcitriol by tumors
- Ectopic parathyroid hormone production
- Medication-induced
- Nutritional
- Granulomatous disease
- Surgical
- Immobilization
- Malignancy
Differential diagnosis of hyperparathyroidism on the basis of hypercalcemia | ||||||||
---|---|---|---|---|---|---|---|---|
Disorder | Mechanism of hypercalcemia | Clinical features | Laboratory findings | Imaging & diagnostic modalities | ||||
PTH | Calcium | Phosphate | Other findings | |||||
Hyperparathyroidism | Primary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a primary process in parathyroid gland. Parathyroid hormone causes increase in serum calcium. |
|
|
↑ | ↓/Normal | Normal/↑ calcitriol | Findings of bone resorption:
Preoperative localization of hyperfunctioning parathyroid gland:
Predicting post-operative success:
|
Secondary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes increase in serum calcium. |
|
|
↓/Normal | ↑ | |||
Tertiary hyperparathyroidism | Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes increase in serum calcium. |
|
|
↑ | ↑ | |||
Familial hypocalciuric hypercalcemia |
|
|
|
Normal/↑ |
| |||
Malignancy[1] | Humoral hypercalcemia of malignancy[2][3][4] | Tumor cells secretes parathyroid hormone related protein (PTHrP) which has similar action as parathyroid hormone. |
|
|
↑ | ↓/Normal | ↑ PTHrP
Normal/↑ calcitriol |
|
Osteolytic tumors | Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia. |
|
|
↑ |
| |||
Production of calcitirol | Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. |
|
|
↑ | ↑ Calcitriol |
| ||
Ectopic parathyroid hormone[5] | Some tumors leads to ectopic production of parathyroid hormone. |
|
|
| ||||
Medication induced | Lithium[6] | Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy. |
|
|
| |||
Thiazide diuretics | Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia |
|
|
-- | ||||
Nutritional | Milk-alkali syndrome | Hypercalcemia is be caused by high intake of calcium carbonate |
|
|
| |||
Vitamin D toxicity | Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. |
|
-- | |||||
Granulomatous disease | Sarcoidosis[9] | Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. |
|
|
|
References
- ↑ Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
- ↑ Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
- ↑ Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
- ↑ Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
- ↑ VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
- ↑ Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
- ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
- ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
- ↑ Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.